Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deucravacitinib long-term extension in moderate to severe Crohn's disease and ulcerative colitis
NL-OMON51428Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of deucravacitinib in Crohn's disease and autoimmune colitis (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Long-term safety and tolerability and Laboratory, ECG, and vital sign safety assessments. Started Nov 2022; status: completed.
02
Drugs
deucravacitinib
03
Conditions
Crohn's diseaseautoimmune colitis
Beyond the preview
Go deeper on NL-OMON51428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51428.